摘要
Abstract
Objective To evaluate the clinical effect and safety of diffe-rent doses of mirtazapine combined with escitalopram oxalate in patients with depression .Methods A total of 120 patients with depression were randomly divided into trial group ( n =60 ) and control group ( n =60 ) . The mirtazapine 30 mg・ d-1 combined with escitalopram oxalate 10 mg・ d-1 were used in trial group , po and mirtazapine 15 mg・ d -1 combined with escitalopram oxalate 10 mg・ d-1 were used in control grou, po.The treatment in both groups lasted for 8 weeks.The data of the hamilton depression scale -17 ( HAMD-17 ) score, montgomery -asberg depression rating scale ( MADRS ) score, clinical efficacy and adverse drug reaction before treatment , 2 weeks, 4 weeks, 6 weeks and 8 weeks after treatment were compared between the two groups . Results After treatment , the HAMD -17 score and MADRS score of two groups were significantly decreased , and the HAMD -17 score and MADRS score of trial group were significantly lower than those of control group ( P<0.05 ) .The clinical efficacy of trial group was significantly higher than the control group ( 93.3% vs 83.3%, P <0.05 ) . The incidence rate of thirst, weak, nausea, dizziness and drowsiness in two groups was not statistically different (P>0.05).However, the rate of weight gain of trial group was significantly higher than that of the control group (P<0.05).Conclusion The effect of high -dose mirtazapine (30 mg・ d-1 ) combined with escitalopram oxalate treat with depression is better than low -dose mirtazapine ( 15 mg・ d-1 ) combined with escitalopram oxalate , but high dose is easy to lead to weight gain .关键词
抑郁症/米氮平/草酸艾司西酞普兰/汉密尔顿抑郁量表17项/蒙哥马利抑郁评定量表Key words
depression/mirtazapine/escitalopram oxalate/Hamilton depression scale -17/Montgomery -asberg depression rating scale分类
医药卫生
